MARSEILLE, France–(BUSINESS WIRE)–#immunotherapy–Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2026 financial calendar: March 26, 2026: Publication of 2025 financial statements May 13, 2026: Publication of revenue and cash position for 1Q2026 May 21, 2026: Annual General Shareholders Meeting September 17, 2026: Publication of half year … [Read more…]
New Clinic Brings Advanced Healthcare to Seattle for Individuals with Scoliosis SEATTLE–(BUSINESS WIRE)–People living with scoliosis in Washington State now have access to world-class, non-surgical treatment options with the Grand Opening of ScoliCare Seattle. This new clinic delivers a patient-centered approach to scoliosis management, combining advanced technology with expert clinical care to improve quality of … [Read more…]
The bipartisan legislation introduced by Congressman Rulli (R-OH-6) and Congressmen Stanton (D-AZ-4) and Pappas (D-NH-1) seeks to strengthen Medicaid nursing services WASHINGTON–(BUSINESS WIRE)–Congressman Rulli (R-OH-6) and Congressmen Stanton (D-AZ-4) and Pappas (D-NH-1) announced the introduction of the Continuous Skilled Nursing Quality Improvement Act of 2025, aimed at improving the quality and accessibility of skilled nursing … [Read more…]
MEMPHIS, Tenn.–(BUSINESS WIRE)–Propeller, the digital platform that connects fans to causes through culture, community and experiences, today announced an opportunity to take action to be entered to win two tickets to Super Bowl LX with proceeds benefitting the lifesaving mission of St. Jude Children’s Research Hospital®: Finding cures. Saving children.® The opportunity is offered in … [Read more…]
New peer-reviewed research provides a clear scientific basis to distinguish authentic kratom from synthetic/adulterated products, advancing consumer safety and evidence-based regulation. CLEVELAND–(BUSINESS WIRE)–The Scientific Association for Botanical Education and Research (SABER) congratulates Steering Committee member Dr. Paula N. Brown and co-authors on the publication of “Elevated 7-Hydroxymitragynine Levels Found in Products Misbranded as Kratom” in … [Read more…]
MHRA authorization to initiate Phase 1/2 clinical trial at U.K. sites follows first U.S. patient dosing with EN-374 for treatment of X-linked chronic granulomatous disease BOSTON–(BUSINESS WIRE)–Ensoma, an in vivo cellular engineering company with a mission to advance the future of medicine through one-time therapies, today announced U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) … [Read more…]
SYDNEY–(BUSINESS WIRE)–Australian biotech All G has raised over A$10 million in a convertible note round ahead of its Series B raise, injecting additional capital for commercial-scale production of its first bovine lactoferrin product due to launch in Q1 2026. In parallel, All G and French global bioactives leader Armor Protéines have established a joint venture … [Read more…]
ZUG, Switzerland–(BUSINESS WIRE)–Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with the Brazilian company Libbs Farmacêutica! Through this strategic partnership, Libbs Farmacêutica will gain exclusive rights to commercialize a cutting-edge biosimilar for autoimmune diseases in the rapidly growing … [Read more…]
BEIJING & SHANGHAI & HONG KONG–(BUSINESS WIRE)–Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing on the Shanghai Stock Exchange STAR Market. This follows the Company’s listing on the Hong Kong Stock Exchange in September 2022 and marks a significant … [Read more…]
SAN DIEGO–(BUSINESS WIRE)–Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced it has filed an amended registration statement on Form F-4 (the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”) that includes a management circular/prospectus and other relevant documents related to various proposals contained therein, … [Read more…]
